Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Lung Neoplasms 12Rectal Neoplasms 11Nasopharyngeal Carcinoma 11Esophageal Neoplasms 11Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumor × sintilimab × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Fujian Haixi Pharmaceuticals Co., Ltd.

Phase 1/2 Active not recruiting
155 enrolled
Other solid neoplasm

Solid Tumor

NCT05119998 2023-08-18

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
48 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡